RGNX (Regenxbio) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


RGNX Regenxbio Inc RGNX
59 GF Score
Price $10.24
GF Value $13.75
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Regenxbio Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Regenxbio's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

RGNX vs LRMR, GLSI, PBYI: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Regenxbio's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Regenxbio's Margin of Safety % (DCF Earnings Based) falls into.


RGNX
59GF Score
Regenxbio Inc RGNX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $10.24 is trading 25.5% below its estimated GF Value™ of $13.75. GuruFocus considers Regenxbio to be Modestly Undervalued.

Key valuation signals for RGNX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $13.75 vs. price of $10.24 (25.5% below fair value)
  • GF Score™: 59/100 with 8 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
59GF Score

Get the complete analysis for RGNX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.24
Price
$13.75
GF Value